EUVIMEDEUVIMED entdecken
Crossref

Resource Utilization for COVID-19 Pneumonia in the ACTIV-1 Trial: A Secondary Data Analysis

Tatyana Der, Derek D. Cyr, Miloni Shah, Anne M. Lachiewicz, Schmid, Andreas, Martín Maillo, Christopher John Lindsell, Hussein R. Al‐Khalidi, Reynold A. Panettieri, William G. Powderly, Akram Khan und 5 weitere

Carolina Digital Repository (University of North Carolina at Chapel Hill) · 07.09.2024

DOI: 10.17615/stmd-4q47 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Carolina Digital Repository (University of North Carolina at Chapel Hill), erschienen am 07.09.2024. Verfasst von Tatyana Der und 16 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronavirus disease 2019 (COVID-19) pneumonia requires considerable healthcare resources. Research Objective Examine if a single dose of infliximab or abatacept, in addition to remdesivir and steroids, decreased resource utilization among participants hospitalized with COVID-19 pneumonia. Study Design and Methods Accelerating COVID-19 Therapeutic Interventions and Vaccines Immunomodulator (ACTIV-1 IM) master protocol was a randomized, placebo-controlled trial examining the potential benefit in time to recovery and mortality of immunomodulators infliximab, abatacept, and cenicriviroc. This observational study performs a secondary analysis of the infliximab, abatacept, and common placebo participants to examine resource utilization. Hospital days, intensive care unit days, days with supplemental oxygen, days with high flow nasal cannula or non-invasive ventilation, ventilator days, and days of extracorporeal membrane oxygenation were each examined. Proportional odds models were used to compare days alive and free of resource use over 28 days between infliximab and placebo groups and between abatacept and placebo groups.

Results

Infliximab infusion, compared to placebo, was associated with greater odds of being alive and free of all interventions tested. Abatacept use was associated only with greater odds of days alive and free of hospitalization and supplemental oxygen.

Interpretation

Infliximab and abatacept use were associated with decreased use of healthcare resources over 28 days compared to placebo, but the absolute differences were small.

Schlagwörter

COVID-19 pneumoniainfliximababataceptcenicrivirocimmunomodulatorshealthcare resource utilizationlength of hospital staymechanical ventilationextracorporeal membrane oxygenationsupplemental oxygen

Zitieren

APA

Der, T., Cyr, D. D., Shah, M., Lachiewicz, A. M., Schmid, Andreas, Maillo, M., Lindsell, C. J., Al‐Khalidi, H. R., Panettieri, R. A., Powderly, W. G., Khan, A., Iyer, V., Bozzette, S. A., Jagpal, S. K., Rauseo, A. M., & members, A. I. S. G. (2024). Resource Utilization for COVID-19 Pneumonia in the ACTIV-1 Trial: A Secondary Data Analysis. Carolina Digital Repository (University of North Carolina at Chapel Hill). https://doi.org/10.17615/stmd-4q47

Vancouver

Der T, Cyr DD, Shah M, Lachiewicz AM, Schmid, Andreas, et al. Resource Utilization for COVID-19 Pneumonia in the ACTIV-1 Trial: A Secondary Data Analysis. Carolina Digital Repository (University of North Carolina at Chapel Hill). 2024. doi:10.17615/stmd-4q47

BibTeX
@article{Der2024,
  author = {Der, Tatyana and Cyr, Derek D. and Shah, Miloni and Lachiewicz, Anne M. and Schmid and Andreas and Maillo, Martín and Lindsell, Christopher John and Al‐Khalidi, Hussein R. and Panettieri, Reynold A. and Powderly, William G. and Khan, Akram and Iyer, Vivek and Bozzette, Samuel A. and Jagpal, Sugeet K. and Rauseo, Adriana M. and members, ACTIV-1 IM study group},
  title = {Resource Utilization for COVID-19 Pneumonia in the ACTIV-1 Trial: A Secondary Data Analysis},
  journal = {Carolina Digital Repository (University of North Carolina at Chapel Hill)},
  year = {2024},
  doi = {10.17615/stmd-4q47}
}
Kostenlos starten →